Some evidence suggests that additional glutaminase activityof ASNase is correlated with toxic side effects.4 On the other hand, it has also been reported that l-ASNase acts effectively in vitro not only against ALL butalso against specific subtypes of acute myeloblastic leukemia (AML)or solid tumors, e.g., breast and pancreatic cancer.5,6 Since AML is a malignant disease that accounts for ∼70% ofacute leukemia cases, further research is still needed to clarifythe utility of l-ASNase as an efficient therapeuticcompound and to expand its clinical applicability.2,3,6. This evidence concerns the gene GLS and acute myeloid leukemia.